SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Keros Therapeutics Approves Up to $5 Million Share Buyback

Keros said the board approved the buyback after the company received a $20 million development milestone payment under its license agreement with Takeda Pharmaceuticals for elritercept.

KROS

Related stories